- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
New Registry for Migraine Patients
The American Migraine Foundation (AMF) has developed a U.S. patient registry and biorepository for migraine. In collaboration with ZS, the AMF also has built a technology solution that sets out to collect a wide range of clinical and biological information from patients with migraine and other headache disorders, and to study that information over the course of an extended period of time.
AMF's American Registry for Migraine Research (ARMR) incorporates biological samples, leverages machine learning, and uses patient-reported outcomes, electronic health record and physician-captured data, and a mobile headache diary application to track the progress of patients over time.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
